Evogene Ltd (EVGN)

[Fress]

Some people are going to become multi millionaires investing in this stock at these levels.

https://www.evogene.com/solutions/#generator


https://www.evogene.com/solutions/#chempass


https://www.evogene.com/solutions/#microboost


When biology meets disruptive technologies
Based on two decades of targeted research, at an investment of tens of millions of dollars, and in collaboration with industry leaders, the CPB (Computational Predictive Biology) platform promotes and optimizes life-science product discovery and development. Integration of deep scientific understandings with big data and artificial intelligence (AI), substantially increases the probability of successful life-science product development, while reducing time and cost.


Gene editing AI platform applications for Biotech and agriculture.


Subsidiaries
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf

Biomica:
2021 Proof of concept, first-in-man study – Immuno-oncology program.


EVGN green gene editing product coming next year can be a blockbuster rivaling Monsantos Roundup which had billions yearly in sales from 2015.

What is an engineered green weed killer product worth in the market these days. coming to market in 2022



https://www.evogene.com/partnerships/


CRISPR-CAS is a revolutionizing genome-editing technology that enables precise genomic changes, which are expected to lead to the development of a new set of products and services. The products and services are expected to include human therapeutics such as CAR-T treatments and curing monogenic diseases, and agricultural uses such as adding nutritional value to food products, among others. This technology can result in products and services in a wide range of markets that could potentially reach a total market size of $500 billion in 2025.


Evogene led the consortium's work package for the development of this first version of a genome-editing design platform. The platform is intended to enable predicting the design of guide-RNA, which directs the CRISPR-CAS to make on-target DNA modifications. Moreover, the developed platform has already produced guide-RNA predictions, which are currently being utilized by the consortium members to perform genome-editing experiments in pharma and agriculture.

These new capabilities are expected to extend the range of Evogene's GeneRator AI solution by supporting products based on changes in genetic elements via genome editing.

https://www.prnewswire.com/il/news-releases/evogene-provides-2020-year-end-update-for-crispr-il-consortium-301200881.html


EVGN Biz Presentation
https://www.evogene.com/wp-content/uploads/2020/05/Evogene_Investor_PPT_May-2020-file.pdf

Evogene website:
https://www.evogene.com/


Genome Stocks-Gene Editing.
$BEAM 5 billion market cap
$EDIT 5.1 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.4 billion market cap
$BLUE 3 billion market cap
$BNGO 850 million market cap
$EVGN 180 million market cap 35 million shares 45% owned by institutions & insiders

$EVGN